MedTrace Logo

A Study of GC3107(BCG Vaccine) in Healthy Infants

NCT03947138 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2022-11-02

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy and safety of GC3107 in healthy infants

Conditions

Interventions

BIOLOGICAL

GC3107

BCG Vaccine

BIOLOGICAL

Intradermal BCG SSI inj.

BCG Vaccine

Sponsors & Collaborators

  • Green Cross Corporation

    lead INDUSTRY

Principal Investigators

  • JongHyun Kim, MD · The Catholic University of Korea St. Vincent's Hospital, Pediatrics

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Max Age
4 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-06
Primary Completion
2022-06-20
Completion
2022-09-06

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03947138 on ClinicalTrials.gov